KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease

BackgroundSelective loss of dopaminergic neurons and diminished putamen gray matter volume (GMV) represents a central feature of Parkinson’s disease (PD). Recent studies have reported specific effects of kinectin 1 gene (KTN1) variants on the putamen GMV.ObjectiveTo examine the relationship of KTN1...

Full description

Bibliographic Details
Main Authors: Qiao Mao, Xiaoping Wang, Bin Chen, Longhua Fan, Shuhong Wang, Yong Zhang, Xiandong Lin, Yuping Cao, Yun-Cheng Wu, Jiawu Ji, Jianying Xu, Jianming Zheng, Huihao Zhang, Chengchou Zheng, Wenzhong Chen, Wenhong Cheng, Xingqun Luo, Kesheng Wang, Lingjun Zuo, Longli Kang, Chiang-Shan R. Li, Xingguang Luo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnins.2020.00651/full
id doaj-83f73b8d21f4414f882750d1dbbf9f6e
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Qiao Mao
Xiaoping Wang
Bin Chen
Longhua Fan
Shuhong Wang
Yong Zhang
Xiandong Lin
Yuping Cao
Yun-Cheng Wu
Jiawu Ji
Jianying Xu
Jianming Zheng
Huihao Zhang
Chengchou Zheng
Wenzhong Chen
Wenhong Cheng
Xingqun Luo
Kesheng Wang
Lingjun Zuo
Longli Kang
Chiang-Shan R. Li
Xingguang Luo
spellingShingle Qiao Mao
Xiaoping Wang
Bin Chen
Longhua Fan
Shuhong Wang
Yong Zhang
Xiandong Lin
Yuping Cao
Yun-Cheng Wu
Jiawu Ji
Jianying Xu
Jianming Zheng
Huihao Zhang
Chengchou Zheng
Wenzhong Chen
Wenhong Cheng
Xingqun Luo
Kesheng Wang
Lingjun Zuo
Longli Kang
Chiang-Shan R. Li
Xingguang Luo
KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
Frontiers in Neuroscience
Parkinson’s disease
KTN1
putamen
substantia nigra
gray matter volume
mRNA expression
author_facet Qiao Mao
Xiaoping Wang
Bin Chen
Longhua Fan
Shuhong Wang
Yong Zhang
Xiandong Lin
Yuping Cao
Yun-Cheng Wu
Jiawu Ji
Jianying Xu
Jianming Zheng
Huihao Zhang
Chengchou Zheng
Wenzhong Chen
Wenhong Cheng
Xingqun Luo
Kesheng Wang
Lingjun Zuo
Longli Kang
Chiang-Shan R. Li
Xingguang Luo
author_sort Qiao Mao
title KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
title_short KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
title_full KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
title_fullStr KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
title_full_unstemmed KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s Disease
title_sort ktn1 variants underlying putamen gray matter volumes and parkinson’s disease
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2020-06-01
description BackgroundSelective loss of dopaminergic neurons and diminished putamen gray matter volume (GMV) represents a central feature of Parkinson’s disease (PD). Recent studies have reported specific effects of kinectin 1 gene (KTN1) variants on the putamen GMV.ObjectiveTo examine the relationship of KTN1 variants, KTN1 mRNA expression in the putamen and substantia nigra pars compacta (SNc), putamen GMV, and PD.MethodsWe examined the associations between PD and a total of 1847 imputed KTN1 single nucleotide polymorphisms (SNPs) in one discovery sample [2,000 subjects with PD vs. 1,986 healthy controls (HC)], and confirmed the nominally significant associations (p < 0.05) in two replication samples (900 PD vs. 867 HC, and 940 PD vs. 801 HC, respectively). The regulatory effects of risk variants on the KTN1 mRNA expression in putamen and SNc and the putamen GMV were tested. We also quantified the expression levels of KTN1 mRNA in the putamen and/or SNc for comparison between PD and HC in five independent cohorts.ResultsSix replicable and two non-replicable KTN1-PD associations were identified (0.009 ≤ p ≤ 0.049). The major alleles of five SNPs, including rs12880292, rs8017172, rs17253792, rs945270, and rs4144657, significantly increased risk for PD (0.020 ≤ p ≤ 0.049) and putamen GMVs (19.08 ≤ β ≤ 60.38; 2.82 ≤ Z ≤ 15.03; 5.0 × 10–51 ≤ p ≤ 0.018). The risk alleles of five SNPs, including rs8017172, rs17253792, rs945270, rs4144657, and rs1188184 also significantly increased the KTN1 mRNA expression in the putamen or SNc (0.021 ≤ p ≤ 0.046). The KTN1 mRNA was abundant in the putamen and/or SNc across five independent cohorts and differentially expressed in the SNc between PD and HC in one cohort (p = 0.047).ConclusionThere was a consistent, significant, replicable, and robust positive relationship among the KTN1 variants, PD risk, KTN1 mRNA expression in putamen, and putamen volumes, and a modest relation between PD risk and KTN1 mRNA expression in SNc, suggesting that KTN1 may play a functional role in the development of PD.
topic Parkinson’s disease
KTN1
putamen
substantia nigra
gray matter volume
mRNA expression
url https://www.frontiersin.org/article/10.3389/fnins.2020.00651/full
work_keys_str_mv AT qiaomao ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT xiaopingwang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT binchen ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT longhuafan ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT shuhongwang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT yongzhang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT xiandonglin ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT yupingcao ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT yunchengwu ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT jiawuji ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT jianyingxu ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT jianmingzheng ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT huihaozhang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT chengchouzheng ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT wenzhongchen ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT wenhongcheng ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT xingqunluo ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT keshengwang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT lingjunzuo ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT longlikang ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT chiangshanrli ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
AT xingguangluo ktn1variantsunderlyingputamengraymattervolumesandparkinsonsdisease
_version_ 1724503480085774336
spelling doaj-83f73b8d21f4414f882750d1dbbf9f6e2020-11-25T03:47:06ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2020-06-011410.3389/fnins.2020.00651497728KTN1 Variants Underlying Putamen Gray Matter Volumes and Parkinson’s DiseaseQiao Mao0Xiaoping Wang1Bin Chen2Longhua Fan3Shuhong Wang4Yong Zhang5Xiandong Lin6Yuping Cao7Yun-Cheng Wu8Jiawu Ji9Jianying Xu10Jianming Zheng11Huihao Zhang12Chengchou Zheng13Wenzhong Chen14Wenhong Cheng15Xingqun Luo16Kesheng Wang17Lingjun Zuo18Longli Kang19Chiang-Shan R. Li20Xingguang Luo21Department of Psychosomatic Medicine, People’s Hospital of Deyang, Deyang, ChinaDepartment of Neurology, Shanghai Tongren Hospital, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Cardiovascular Medicine, Fujian Provincial Hospital, Fuzhou, ChinaQingpu Branch, Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Neurology, Shanghai Tongren Hospital, Shanghai Jiao Tong University, Shanghai, ChinaTianjin Mental Health Center, Tianjin, ChinaLaboratory of Radiation Oncology and Radiobiology, Fujian Provincial Cancer Hospital, Teaching Hospital of Fujian Medical University, Fuzhou, ChinaDepartment of Psychiatry, Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Psychiatry, Fuzhou Neuropsychiatric Hospital, Fujian Medical University, Fuzhou, China0Zhuhai Municipal Maternal and Children’s Health Hospital, Zhuhai, China1Huashan Hospital, Fudan University School of Medicine, Shanghai, China2The First Affiliated Hospital, Fujian Medical University, Fuzhou, China3Minqing Psychiatric Hospital, Minqing, China4Department of Psychiatry, Shanghai Mental Health Center, Shanghai, China4Department of Psychiatry, Shanghai Mental Health Center, Shanghai, China5Department of Clinical Medicine, College of Integrated Traditional Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China6Department of Family and Community Health, School of Nursing, Health Sciences Center, West Virginia University, Morgantown, WV, United States7Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States8Key Laboratory for Molecular Genetic Mechanisms and Intervention Research on High Altitude Diseases of Tibet Autonomous Region, Xizang Minzu University School of Medicine, Xiangyang, China7Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States9Biological Psychiatry Research Center, Beijing Huilongguan Hospital, Beijing, ChinaBackgroundSelective loss of dopaminergic neurons and diminished putamen gray matter volume (GMV) represents a central feature of Parkinson’s disease (PD). Recent studies have reported specific effects of kinectin 1 gene (KTN1) variants on the putamen GMV.ObjectiveTo examine the relationship of KTN1 variants, KTN1 mRNA expression in the putamen and substantia nigra pars compacta (SNc), putamen GMV, and PD.MethodsWe examined the associations between PD and a total of 1847 imputed KTN1 single nucleotide polymorphisms (SNPs) in one discovery sample [2,000 subjects with PD vs. 1,986 healthy controls (HC)], and confirmed the nominally significant associations (p < 0.05) in two replication samples (900 PD vs. 867 HC, and 940 PD vs. 801 HC, respectively). The regulatory effects of risk variants on the KTN1 mRNA expression in putamen and SNc and the putamen GMV were tested. We also quantified the expression levels of KTN1 mRNA in the putamen and/or SNc for comparison between PD and HC in five independent cohorts.ResultsSix replicable and two non-replicable KTN1-PD associations were identified (0.009 ≤ p ≤ 0.049). The major alleles of five SNPs, including rs12880292, rs8017172, rs17253792, rs945270, and rs4144657, significantly increased risk for PD (0.020 ≤ p ≤ 0.049) and putamen GMVs (19.08 ≤ β ≤ 60.38; 2.82 ≤ Z ≤ 15.03; 5.0 × 10–51 ≤ p ≤ 0.018). The risk alleles of five SNPs, including rs8017172, rs17253792, rs945270, rs4144657, and rs1188184 also significantly increased the KTN1 mRNA expression in the putamen or SNc (0.021 ≤ p ≤ 0.046). The KTN1 mRNA was abundant in the putamen and/or SNc across five independent cohorts and differentially expressed in the SNc between PD and HC in one cohort (p = 0.047).ConclusionThere was a consistent, significant, replicable, and robust positive relationship among the KTN1 variants, PD risk, KTN1 mRNA expression in putamen, and putamen volumes, and a modest relation between PD risk and KTN1 mRNA expression in SNc, suggesting that KTN1 may play a functional role in the development of PD.https://www.frontiersin.org/article/10.3389/fnins.2020.00651/fullParkinson’s diseaseKTN1putamensubstantia nigragray matter volumemRNA expression